Lykos Therapeutics (formerly MAPS PBC)
Andrew "Mo" Septimus is the Chief Financial Officer at Lykos Therapeutics, involved in drug development and commercialization. Before his current role, he was the CFO at MAPS and Izun Pharmaceuticals, and led the sale of ebbu to Canopy Growth Corp. With a background in finance and agribusiness economics, he has held various leadership positions in companies like Algae Systems, Kuzari Group, and the National Archives.
Lykos Therapeutics (formerly MAPS PBC)
At Lykos Therapeutics, our mission is to transform the way mental health is treated. We aspire to challenge the status quo through the development of novel therapies and therapeutic approaches to treat mental health conditions. With 30+ years of experience researching psychedelic-assisted therapies, we remain focused on following rigorous science from which we can develop and commercialize novel treatment options. Founded in 2014 by the non-profit Multidisciplinary Association for Psychedelic Studies (“MAPS”), we are a for-profit public benefit corporation (“PBC”). As a PBC, we consider the impact of our decisions on society just as we think about financial implications. Everything we do is looked at through a public benefit lens. To learn more, visit us at www.lykospbc.com.